New research has demonstrated the potential benefits that the antiepileptic drug (AED) brivaracetam can provide when administered intravenously.Conducted by the Mid-Atlantic Epilepsy and Sleep Center in Bethesda in the US, the study aimed to examine the feasibility of offering the drug intravenously as an alternative for those unable to benefit from oral therapy.A total of 105 people, aged between 16 and 70 years, were enrolled to the study. All had focal or generalised epilepsy that was uncontrolled, despite taking one or two AEDs.According to the results, published in the medical journal Epilepsia, the rate of treatment-associated adverse effects was similar whether intravenous brivaracetam was initiated first or whether it followed a course of oral therapy.It was also shown that the intravenous therapy offered a similar level of safety and tolerability, whether it was administered as a large bolus dose (a single, large quantity) or through a more gradual infusion process.The research concludes: “Intravenous brivaracetam may be an option for patients who are unable to receive oral brivaracetam.”Click here for more articles about anti-epileptic drugs and pregnancy risks.